QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
67.16
+4.14 (+6.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close63.02
Open63.00
Bid66.05 x 800
Ask67.50 x 800
Day's Range63.00 - 67.50
52 Week Range36.20 - 82.49
Volume497,906
Avg. Volume395,919
Market Cap2.975B
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-2.99
Earnings DateApr 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est85.56
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Done Buying Uniqure NV (QURE)?
    Insider Monkey

    Hedge Funds Done Buying Uniqure NV (QURE)?

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Analysts Have Just Cut Their uniQure N.V. (NASDAQ:QURE) Revenue Estimates By 16%
    Simply Wall St.

    Analysts Have Just Cut Their uniQure N.V. (NASDAQ:QURE) Revenue Estimates By 16%

    Market forces rained on the parade of uniQure N.V. (NASDAQ:QURE) shareholders today, when the analysts downgraded...

  • GlobeNewswire

    uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 14, 2020 (GLOBE NEWSWIRE) --  uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, presented new preclinical data on its gene therapy candidates AMT-150 for Spinocerebellar Ataxia type 3, AMT-190 for Fabry disease, and AMT-180 for the treatment of Hemophilia A. The data are featured in presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. “Our collective presence at ASGCT showcases the breadth of uniQure’s gene therapy expertise and leadership, including our research capabilities and excellence in developing and manufacturing novel gene therapies,” stated Matt Kapusta, chief executive officer at uniQure.

  • JPMorgan Genetic-Therapies Fund Finds Success in Covid-19 Era
    Bloomberg

    JPMorgan Genetic-Therapies Fund Finds Success in Covid-19 Era

    (Bloomberg) -- JPMorgan Asset Management now has more than $400 million in its Thematics - Genetic Therapies fund launched in October, just before the world’s need for such technologies came into focus with the arrival of Covid-19.The fund uses natural-language processing focused on keywords in company documents along with a revenue screen to find firms that best fit the genetic-therapies theme, according to Sherene Ban, an investment specialist at JPMorgan Asset. The portfolio managers also factor in things like liquidity and quality to make decisions on the fund’s composition, Ban said in an interview Friday.The fund has a 20% one-month return that puts it in the 94th percentile among its peers, according to data compiled by Bloomberg. Of course, the biotech theme has done well generally -- the S&P Biotechnology Select Industry Index is up 9.5% this year versus a decline of 10% for the S&P Total Market Index.“We’re starting to see a lot of client interest because it actually behaved as a defensive fund” through the market turmoil of the past few months, Ban said. She noted that technologies related to genetic therapies -- such as genetic sequencing of the virus and vaccine development -- have been central to efforts to combat Covid-19, spurring price gains of stocks in the space.The fund’s top three holdings as of March 31 were Iovance Biotherapeutics Inc., Regeneron Pharmaceuticals Inc. and uniQure NV. It contains about 100 stocks to provide diversified access to the overall theme, and has about a third of its portfolio in companies with under $2 billion in market capitalization, Ban said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

    uniQure (QURE) delivered earnings and revenue surprises of 26.74% and -94.09%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress

    ~ Completed Target Patient Dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B ~ ~ Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting.

  • GlobeNewswire

    uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting

    LEXINGTON, Mass. and AMSTERDAM, April 28, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe.

  • Earnings Preview: uniQure (QURE) Q1 Earnings Expected to Decline
    Zacks

    Earnings Preview: uniQure (QURE) Q1 Earnings Expected to Decline

    UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Sanofi CEO's Comments Lit A Fire Under Gene Therapy Stocks
    Investor's Business Daily

    Why Sanofi CEO's Comments Lit A Fire Under Gene Therapy Stocks

    Uniqure stock popped Friday on a suggestion French pharma giant Sanofi could make a play for the gene therapy biotech company. Uniqure latest-stage effort is in a hemophilia B treatment.

  • Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

  • GlobeNewswire

    uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors

    LEXINGTON, Mass. and AMSTERDAM, April 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the nomination of Leonard E. Post, Ph.D. to stand for election to its Board of Directors. Dr. Post, who will also chair the Company’s Research & Development Committee, has extensive biotechnology industry experience including previous global R&D leadership roles at BioMarin and Onyx Pharmaceuticals. "It is with great pleasure that we nominate Len to the uniQure board,” stated Matthew Kapusta, chief executive officer of uniQure.

  • GlobeNewswire

    uniQure to Participate in Multiple Upcoming Investor Conferences in April

    LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe.

  • Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • Biotech delays U.S. gene therapy launch due to outbreak, FDA discord
    American City Business Journals

    Biotech delays U.S. gene therapy launch due to outbreak, FDA discord

    One of the biotech industry’s up-and-coming gene therapy companies is further delaying its plans for a U.S. drug launch, citing disagreements with FDA officials and the COVID-19 pandemic.

  • GlobeNewswire

    uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced it has achieved the targeted dosing of patients in the HOPE-B pivotal trial of etranacogene dezaparvovec (AMT-061), an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. The targeted number of patients to be dosed per the clinical trial protocol was 50. “I am very proud of the entire uniQure team, our investigators, study coordinators and the hemophilia patient communities who helped make this major milestone possible,” stated Matt Kapusta, chief executive officer of uniQure.

  • Biotech pushes blood disorder cell therapy to clinic after $80M round
    American City Business Journals

    Biotech pushes blood disorder cell therapy to clinic after $80M round

    With new financing in its pocket, a Flagship Pioneering-backed cell therapy startup is ready to begin its first in-human tests of a rare disease treatment.

  • GlobeNewswire

    uniQure to Participate in Multiple Upcoming Industry Conferences in March

    LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe.

  • UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates

    uniQure (QURE) delivered earnings and revenue surprises of -24.36% and 49.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters

    LEXINGTON, Mass. and AMSTERDAM, The Netherlands, March 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, and Gen-X, a spin-off company from the Netherlands Cancer Institute, today announced that they have signed an exclusive research collaboration and license agreement with Gen-X, with an option for uniQure to acquire Gen-X, to identify novel synthetic promoters for use in gene therapy products. Gen-X performs functional annotation of the non-coding genome using its proprietary Survey of Regulatory Elements (SuRE) technology.

  • GlobeNewswire

    uniQure Announces 2019 Financial Results and Highlights Recent Company Progress

    ~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in.

  • GlobeNewswire

    uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of multiple new preclinical data on AMT-130, its investigational AAV gene therapy for the treatment of Huntington’s disease (HD), at the 15th Annual CHDI Huntington’s disease Therapeutics Conference in Palm Springs, California. “Our data presentations at CHDI illustrate the increasing potential of AMT-130 to target the highly toxic exon 1 protein fragment, achieve broad vector biodistribution across several animal species and show meaningful activity using the presence of extracellular vesicles as a potential biomarker,” stated Sander van Deventer, M.D., Ph.D., executive vice president, research & product development of uniQure.

  • Why Earnings Season Could Be Great for uniQure (QURE)
    Zacks

    Why Earnings Season Could Be Great for uniQure (QURE)

    uniQure (QURE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Before You Buy uniQure N.V. (NASDAQ:QURE), Consider Its Volatility
    Simply Wall St.

    Before You Buy uniQure N.V. (NASDAQ:QURE), Consider Its Volatility

    If you own shares in uniQure N.V. (NASDAQ:QURE) then it's worth thinking about how it contributes to the volatility of...

  • UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks

    UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

    LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.